Skip to main content

Advertisement

Table 3 Univariate and multivariate analyses of the prognostic factors of PFS in AGC patients with SPM (n = 129)

From: Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study

Variables Univariate analysis Multivariate analysis
HR [95% CI] p-value HR [95% CI] p-value
Regimen
 FP (vs. F) 0.44 [0.30–0.66] < 0.01 0.41 [0.26–0.64] < 0.01
Age
 ≥65 (vs. < 65) 0.99 [0.67–1.45] 0.95    
Sex
 Female (vs. male) 0.96 [0.65–1.41] 0.82    
ECOG PS
 2–4 (vs. 0–1) 1.28 [0.86–1.90] 0.22 1.04 [0.68–1.60] 0.86
Histology
 Intestinal (vs. diffuse) 0.81 [0.48–1.39] 0.45    
 Unknown (vs. diffuse) NA   NA    
Disease status
 Recurrent (vs. advanced) 0.48 [0.20–1.19] 0.11 0.60 [0.24–1.50] 0.27
Primary site
 GEJ (vs. stomach) 0.55 [0.20–1.53] 0.25    
No. of metastatic sites
 ≥3 (vs. 1–2) 1.28 [0.86–1.90] 0.22    
Target lesion
 Absence (vs. presence) 1.03 [0.69–1.53] 0.90    
Subtype of SPM
 Inadequate oral intake (vs. massive ascites) 0.66 [0.41–1.07] 0.09 0.64 [0.40–1.04] 0.07
 Both (vs. massive ascites) 0.88 [0.54–1.44] 0.61 0.57 [0.34–0.96] 0.03
Serum albumin level
 < 3.1 g/ml (vs. > 3.1 g/ml) 1.10 [0.74–1.62] 0.65    
  1. AGC advanced gastric cancer, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, GEJ gastroesophageal junction, HR hazard ratio, NA not assessed, PFS progression-free survival, SPM severe peritoneal metastasis